Carisma Therapeutics, Inc.

CARM · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$44,717-$9,774-$9,266-$17,635
Dep. & Amort.$0$0$661$669
Deferred Tax$0$0$0$0
Stock-Based Comp.$421$431$508$852
Change in WC$0-$1,395-$2,961$8,007
Other Non-Cash-$43,230$4,834$991-$245
Operating Cash Flow$1,908-$5,904-$10,067-$8,352
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$163$524$0
Investing Cash Flow$0$163$524$0
Financing Activities
Debt Repay.$0$0-$304-$271
Stock Issued$0$0$5-$23
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$1,130$0-$327-$326
Financing Cash Flow-$1,130$0-$626-$620
Forex Effect$0$0$0$0
Net Chg. in Cash$778-$5,741-$10,169-$8,972
Supplemental Information
Beg. Cash$1,999$7,740$17,909$26,881
End Cash$2,777$1,999$7,740$17,909
Free Cash Flow$1,908-$5,904-$10,067-$8,352
Carisma Therapeutics, Inc. (CARM) Financial Statements & Key Stats | AlphaPilot